Dr Donal McLornan is a Consultant in Haematology and Stem Cell Transplantation, clinically specialising in Haemato-oncology and Stem Cell Transplantation. He has a particular interest in Myeloproliferative Neoplasms (MPN), CML, Myelodysplasia, Acute Myeloid Leukaemia and Allogeneic Stem Cell Transplantation.

Dr McLornan is the current Chair of the Chronic Malignancies Working Party of EBMT. He also the Co-Chair of the EBMT Scientific Council. He is the Chair of the UK MPN Clinical Study Group from 2022- 2026. He has extensive clinical trial expertise and is the Chief Investigator or Principal Investigator of multiple clinical trials in the field of MPN. He is a global key opinion Initial Request Form leader in the management of Myelofibrosis, Polycythaemia Vera and Essential Thrombocythaemia and related disorders.

Dr McLornan graduated in 1999 from Queen's University Belfast with Honours, undertaking a further one-year period in Hammersmith Hospital, specialising in Allogeneic and Autologous Stem Cell Transplantation for post-graduate training. During this postgraduate training, he was awarded a prestigious MRC fellowship and completed a PhD investigating drug resistance in Acute Myeloid Leukaemia for which he received several awards. He has also authored over 200 papers and has a special research interest in Myeloproliferative Neoplasms (MPN). He is a member of EHA, EBMT and BSH, while regularly speaking internationally on MPN, MDS and allogeneic SCT